R3 Vascular Adds Two Senior Executives to Accelerate Commercialization

R3 Vascular Inc. appointed two senior executives to support the company's push toward commercialization of its bioresorbable scaffold technology for peripheral artery disease. Robert Spanos joins as vice president of global market development. Katie Segreto becomes vice president of finance and corporate controller.

The Mountain View, California-based medical device company is developing MAGNITUDE, a fully bioresorbable drug-eluting scaffold coated with sirolimus. The device is designed to provide temporary vessel support and then dissolve over time as the artery heals. R3 Vascular is currently enrolling patients in the ELITE clinical trial, which is evaluating the scaffold in tibial vessels for critical limb ischemia.

Christopher M. Owens, president and CEO, said the appointments come as the company accelerates trial enrollment and builds the infrastructure needed for a future commercial launch. He called both executives "instrumental" to advancing clinical development and scaling the organization.

Spanos brings more than 20 years of experience in peripheral vascular markets. He previously held senior leadership roles at Emblok Inc., AngioDynamics, and Eximo Medical, where he worked on IDE trials, FDA 510(k) submissions, and product launches. He also served at IDev Technologies, Mercator MedSystems, FoxHollow Technologies, and Guidant Endovascular Solutions.

"Bob's deep experience in peripheral vascular markets and successful product launches will strengthen our commercial strategy and market expansion efforts," Owens said in a statement.